Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trials referral resource

B D Cheson

    Oncology (Williston Park, N.Y.)
    |October 1, 1990
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia.

    Leukemia & lymphoma·2016
    Same author

    Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

    Leukemia·2015
    Same author

    Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.

    Blood cancer journal·2014
    Same journal

    Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

    Oncology (Williston Park, N.Y.)·2026
    Same journal

    Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

    Oncology (Williston Park, N.Y.)·2026
    Same journal

    Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

    Oncology (Williston Park, N.Y.)·2026
    Same journal

    Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

    Oncology (Williston Park, N.Y.)·2026
    Same journal

    Before Certainty.

    Oncology (Williston Park, N.Y.)·2026
    Same journal

    Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

    Oncology (Williston Park, N.Y.)·2026
    See all related articles